ES2166097T3 - Glicoconjugados de neisseria meningitidis de serogrupo b y procedimientos para usarlos. - Google Patents

Glicoconjugados de neisseria meningitidis de serogrupo b y procedimientos para usarlos.

Info

Publication number
ES2166097T3
ES2166097T3 ES97936364T ES97936364T ES2166097T3 ES 2166097 T3 ES2166097 T3 ES 2166097T3 ES 97936364 T ES97936364 T ES 97936364T ES 97936364 T ES97936364 T ES 97936364T ES 2166097 T3 ES2166097 T3 ES 2166097T3
Authority
ES
Spain
Prior art keywords
glycoconjugates
neisseria meningitidis
neisseria
vaccine formulations
serogrupo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97936364T
Other languages
English (en)
Other versions
ES2166097T5 (es
Inventor
Robert C Seid
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21820678&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2166097(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiron Corp filed Critical Chiron Corp
Application granted granted Critical
Publication of ES2166097T3 publication Critical patent/ES2166097T3/es
Publication of ES2166097T5 publication Critical patent/ES2166097T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/831—Drug, bio-affecting and body treating compositions involving capsular polysaccharide of bacterium, e.g. polyribosyl ribitol phosphate
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/832—Drug, bio-affecting and body treating compositions involving bacterial toxin that has modified amino acid sequence
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition
    • Y10S977/917—Vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE EN GENERAL A NUEVOS GLUCOCONJUGADOS DEL GRUPO SEROLOGICO B DE LA NEISSERIA MENINGITIDIS. MAS CONCRETAMENTE, LA INVENCION PERTENECE A GLUCOCONJUGADOS FORMADOS A PARTIR DE UN DERIVADO DE OLISACARIDO CAPSULAR DEL SEROGRUPO B DE LA NEISSERIA MENINGITIDIS (DERIVADO MENBOS) EN EL QUE GRUPOS N - ACETILO DEL RESIDUO DE ACIDO SIALICO SON SUSTITUIDOS POR GRUPOS N - ACILO. LA INVENCION SE REFIERE IGUALMENTE A FORMULACIONES DE VACUNAS QUE CONTIENEN LOS GLUCOCONJUGADOS, PROCEDIMIENTOS PARA REALIZAR LAS FORMULACIONES DE VACUNAS Y PROCEDIMIENTOS PARA EL USO DE DICHAS FORMULACIONES PARA EL TRATAMIENTO O PREVENCION DE LA ENFERMEDAD PRODUCIDA POR EL GRUPO SEROLOGICO B DE LA NEISSERIA MENINGITIDIS O DE LA E. COLI K1, EN UN SUJETO MAMIFERO.
ES97936364T 1996-08-27 1997-08-04 Glicoconjugados de neisseria meningitidis de serogrupo b y procedimientos para usarlos. Expired - Lifetime ES2166097T5 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2445496P 1996-08-27 1996-08-27
US24454P 1996-08-27

Publications (2)

Publication Number Publication Date
ES2166097T3 true ES2166097T3 (es) 2002-04-01
ES2166097T5 ES2166097T5 (es) 2007-03-16

Family

ID=21820678

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97936364T Expired - Lifetime ES2166097T5 (es) 1996-08-27 1997-08-04 Glicoconjugados de neisseria meningitidis de serogrupo b y procedimientos para usarlos.

Country Status (11)

Country Link
US (2) US6638513B2 (es)
EP (1) EP0939647B2 (es)
JP (2) JP4162267B2 (es)
AT (1) ATE208629T1 (es)
CA (1) CA2264735C (es)
DE (1) DE69708318T3 (es)
DK (1) DK0939647T4 (es)
ES (1) ES2166097T5 (es)
HK (1) HK1021145A1 (es)
PT (1) PT939647E (es)
WO (1) WO1998008543A1 (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4150082B2 (ja) 1996-08-27 2008-09-17 カイロン コーポレイション 独特の髄膜炎菌性ｂエピトープを規定するモノクローナル抗体およびワクチン組成物の調製におけるそれらの使用
DE69708318T3 (de) * 1996-08-27 2006-11-16 Novartis Vaccines and Diagnostics, Inc., Emeryville Neisseria meningitidis serogruppe b glykokonjugate und verfahren zu deren verwendung
JP2002506448A (ja) 1997-06-24 2002-02-26 カイロン コーポレイション 抗髄膜炎菌ワクチン組成物を使用して成体を免疫する方法
GB9808866D0 (en) * 1998-04-24 1998-06-24 Smithkline Beecham Biolog Novel compounds
ES2485940T3 (es) * 1998-05-29 2014-08-14 Novartis Vaccines And Diagnostics, Inc. Combinación de vacunas contra Meningitis B/C
US20030072764A1 (en) * 2001-04-05 2003-04-17 O'hagan Derek Mucosal boosting following parenteral priming
AU2002252638A1 (en) 2001-04-17 2002-10-28 Children's Hospital Oakland Research Institute Molecular mimetics of meningococcal b epitopes which elicit functionally active antibodies
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
DK1777236T3 (en) * 2002-03-26 2017-02-27 Glaxosmithkline Biologicals Sa MODIFIED SUCCARIDES WHICH IMPROVED WATER STABILITY FOR USE AS A MEDICINE
EP2191844B1 (en) 2003-01-30 2014-03-05 Novartis AG Injectable vaccines against multiple meningococcal serogroups
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
GB0408977D0 (en) 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
US8148335B2 (en) 2004-06-23 2012-04-03 Children's Hospital & Research Center Oakland De-N-acetyl sialic acid antigens, antibodies thereto, and methods of use in cancer therapy
CA2568982A1 (en) * 2004-06-23 2006-01-05 Children's Hospital & Research Center At Oakland Polysaccharide derivatives and uses in induction of an immune response
GB0611914D0 (en) * 2006-06-15 2006-07-26 Teti Giuseppe Peptides that mimic non-human cross-reactive protective epitopes of the group Bmeningococcal capsulsar polysaccharide
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
AU2008272792B2 (en) * 2007-07-03 2014-03-06 Children's Hospital & Research Center At Oakland Oligosialic acid derivatives, methods of manufacture, and immunological uses
JP5523313B2 (ja) 2007-07-03 2014-06-18 チルドレンズ ホスピタル アンド リサーチ センター アット オークランド ポリシアル酸誘導体、製造方法、ならびにがん抗原産生の増強およびターゲティングにおける使用
US20130071422A1 (en) * 2010-03-18 2013-03-21 Michele Pallaoro Adjuvanted vaccines for serogroup b meningococcus
HRP20210242T4 (hr) 2010-08-23 2024-05-10 Wyeth Llc Stabilne formulacije antigena iz bakterije neisseria meningitidis rlp2086
CN103096920B (zh) 2010-09-10 2016-03-23 惠氏有限责任公司 脑膜炎奈瑟球菌orf2086抗原的非脂质化变体
MY163674A (en) 2011-07-01 2017-10-13 Ngm Biopharmaceuticals Inc Compositions, uses and method for treatment of metabolic disorders and diseases
BR122016004924A2 (pt) 2012-03-09 2019-07-30 Pfizer Inc. Polipeptídeo isolado e composições imunogênicas compreendendo os mesmos
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
IN2015DN00552A (es) 2012-07-19 2015-06-26 Redwood Bioscience Inc
PT2885010T (pt) 2012-08-16 2020-03-11 Ipierian Inc Métodos de tratamento de uma tauopatia
AU2013334229B2 (en) 2012-10-25 2018-02-15 Bioverativ Usa Inc. Anti-complement C1s antibodies and uses thereof
DK2914291T3 (da) 2012-11-02 2022-05-16 Bioverativ Usa Inc Anti-komplement-c1s-antistoffer og anvendelser deraf
AU2013352363B2 (en) 2012-11-28 2018-04-12 Ngm Biopharmaceuticals, Inc. Compositions and methods for treatment of metabolic disorders and diseases
HRP20221438T1 (hr) 2012-12-20 2023-02-03 Pfizer Inc. Postupak glikokonjugiranja
DK2938740T3 (da) 2012-12-27 2022-06-20 Ngm Biopharmaceuticals Inc Kimære fgf19-peptider til anvendelse til behandling af galdesyrelidelser
JP6446377B2 (ja) 2013-03-08 2018-12-26 ファイザー・インク 免疫原性融合ポリペプチド
JP6446443B2 (ja) 2013-06-10 2018-12-26 アイピエリアン，インコーポレイティド タウオパチーの処置方法
CA2923129C (en) 2013-09-08 2020-06-09 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
EP3074420A2 (en) 2013-11-27 2016-10-05 Ipierian, Inc. Methods of treating a tauopathy
CN107108711B (zh) 2014-10-23 2021-11-23 恩格姆生物制药公司 包含肽变异体的药物组合物及其使用方法
AU2016221318B2 (en) 2015-02-19 2020-06-25 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
JP6728352B2 (ja) 2015-11-09 2020-07-22 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド 胆汁酸に関係した障害の治療方法
BR112018070357A2 (pt) 2016-04-04 2019-01-29 Bioverativ Usa Inc anticorpos anticomplemento contra o fator bb e seus usos
AU2018215585B2 (en) 2017-01-31 2022-03-17 Pfizer Inc. Neisseria meningitidis compositions and methods thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4902506A (en) † 1983-07-05 1990-02-20 The University Of Rochester Immunogenic conjugates
IT1187753B (it) * 1985-07-05 1987-12-23 Sclavo Spa Coniugati glicoproteici ad attivita' immunogenica trivalente
US4727136A (en) † 1985-10-01 1988-02-23 Canadian Patents And Development Ltd. Modified meningococcal group B polysaccharide for conjugate vaccine
NZ223009A (en) * 1986-12-31 1990-06-26 Nl Rivm Of Thoven Oligosaccharides containing d-ribose d-ribitol and phosphate units mimicing haemophilus influenzae type b antigens
AU641715B2 (en) † 1989-12-14 1993-09-30 National Research Council Of Canada Improved meningococcal polysaccharide conjugate vaccine
US5153312A (en) * 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
CA2059692C (en) * 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
CA2059693C (en) * 1991-01-28 2003-08-19 Peter J. Kniskern Polysaccharide antigens from streptococcus pneumoniae
US5354853A (en) * 1993-03-12 1994-10-11 Genzyme Corporation Phospholipid-saccharide conjugates
GB9422096D0 (en) 1994-11-02 1994-12-21 Biocine Spa Combined meningitis vaccine
WO1996040225A1 (en) * 1995-06-07 1996-12-19 Alberta Research Council Immunogenic and immunostimulatory oligosaccharide compositions and methods of making and using them
US5811102A (en) * 1995-06-07 1998-09-22 National Research Council Of Canada Modified meningococcal polysaccharide conjugate vaccines
DE69708318T3 (de) * 1996-08-27 2006-11-16 Novartis Vaccines and Diagnostics, Inc., Emeryville Neisseria meningitidis serogruppe b glykokonjugate und verfahren zu deren verwendung
JP4150082B2 (ja) 1996-08-27 2008-09-17 カイロン コーポレイション 独特の髄膜炎菌性ｂエピトープを規定するモノクローナル抗体およびワクチン組成物の調製におけるそれらの使用
JP2002506448A (ja) * 1997-06-24 2002-02-26 カイロン コーポレイション 抗髄膜炎菌ワクチン組成物を使用して成体を免疫する方法
CA2301942C (en) 1997-08-27 2011-05-31 Chiron Corporation Molecular mimetics of meningococcal b epitopes

Also Published As

Publication number Publication date
JP4162267B2 (ja) 2008-10-08
ATE208629T1 (de) 2001-11-15
PT939647E (pt) 2002-04-29
JP2001500540A (ja) 2001-01-16
US7169392B2 (en) 2007-01-30
DE69708318D1 (de) 2002-01-03
EP0939647B2 (en) 2006-07-12
HK1021145A1 (en) 2000-06-02
US20020034518A1 (en) 2002-03-21
JP2008201793A (ja) 2008-09-04
EP0939647B1 (en) 2001-11-14
US6638513B2 (en) 2003-10-28
ES2166097T5 (es) 2007-03-16
CA2264735C (en) 2008-01-29
DK0939647T4 (da) 2006-10-23
DE69708318T2 (de) 2002-07-11
EP0939647A1 (en) 1999-09-08
DK0939647T3 (da) 2002-04-02
DE69708318T3 (de) 2006-11-16
CA2264735A1 (en) 1998-03-05
WO1998008543A1 (en) 1998-03-05
US20040052805A1 (en) 2004-03-18

Similar Documents

Publication Publication Date Title
ES2166097T3 (es) Glicoconjugados de neisseria meningitidis de serogrupo b y procedimientos para usarlos.
YU24391A (sh) Poboljšana meningokokna polisaharid kon-jugovana vakcina
CY1109202T1 (el) Συνθεσεις που περιεχουν αντιγονα απο τους οροτυπους b και c της neisseria meningitidis οπως και επιπλεον αντιγονα απο τον οροτυπο α
ATE505478T1 (de) Molekular-mimetika von meningokokkalen b epitopen
BR0011000A (pt) Métodos para prevenir ou tratar uma doença associada com depósitos amilóides de ab no cérebro de um paciente, para avaliar um anticorpo quanto á atividade de remoção de uma entidade biológica fisicamente associada com um antìgeno e para detectara um depósito amilóide em um paciente, composição farmacêutica, e, conjunto de diagnóstico
ITFI920058A1 (it) Composti coniugati formati da proteine heat shock (hsp) e oligo-polisaccaridi, loro uso per la produzione di vaccini.
DK0544779T3 (da) Heterocykliske forbindelser og deres fremstilling og anvendelse
NO912369D0 (no) Meningokokk-klasse-1-ytre-membranvaksine.
ES2119836T3 (es) Aparato para aplicar sujetadores quirurgicos.
BR9811260A (pt) Pequenas moléculas úteis no tratamento de doença inflamatória
HK1034460A1 (en) Combination meningitidis b/c vaccines
BRPI0410341A (pt) conjugados de polissacarìdeo-proteìna derivatizados de meningococos multivalente e vacina
DK0749429T3 (da) 3,5-Disubstituerede og 3,4,5-trisubstituerede 2-isoxazoliner og isoxazoler, fremgangsmåder til deres fremstilling og deres
NO972391D0 (no) 2-substituerte 1,2,5-tiadiazolidin-3-on 1,1-dioksider og preparater og metoder for anvendelse derav
DE58902712D1 (de) N-acetylglucosamin-zubereitungen zur buccalen anwendung.
DE69621786D1 (de) Aminotetralinderivat zur behandlung von herzkreislauferkrankung
AR041116A1 (es) Metodos para tratar pacientes que sufen el sindrome de piernas inquietas o desordenes relacionados
SE9400524D0 (sv) Energipreparat
DK598184A (da) 3-aryl-1,2-benzisoxazolsulfonyl- og -sulfinylalkansyrer og farmaceutisk acceptable salte deraf, deres fremstilling og anvendelse som laegemidler
PT1535928E (pt) Composições de vacina compreendendo proteínas omp85 de neisseria gonorrhoeae e neisseria meningitidis

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 939647

Country of ref document: ES